Novo Nordisk first out of the gate with oral weight-loss drug, and its stock jumps

Core Viewpoint - A relief rally is occurring in Novo Nordisk's stock after a challenging year, during which it lost market position to its main competitor, Eli Lilly [1] Company Summary - Novo Nordisk experienced a difficult year, marked by a decline in stock performance [1] - The company is currently witnessing a recovery in its stock price, indicating a potential turnaround [1] Industry Summary - The competitive landscape in the pharmaceutical industry, particularly in the diabetes treatment sector, is highlighted by the rivalry between Novo Nordisk and Eli Lilly [1] - The performance of Novo Nordisk's stock is being closely monitored as it attempts to regain its footing against competitors [1]